10-K: Viking Therapeutics Reports Positive 2024 Results, Advances Pipeline

Viking Therapeutics' 2024 10-K filing highlights clinical advancements in VK2735 and VK2809, alongside financial stability for continued development.

Summary

• Viking Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing novel therapies for metabolic and endocrine disorders.
• The company completed a Phase 1 trial of VK2735, a dual agonist of GLP-1 and GIP receptors, and initiated a Phase 2 clinical trial (VENTURE) in obese patients.
• VENTURE study results showed statistically significant reductions in mean body weight, up to 14.7% from baseline, in patients receiving VK2735.
• Based on FDA feedback, Viking expects to initiate Phase 3 clinical studies of subcutaneous VK2735 in the first half of 2025.
• A Phase 1 clinical study evaluating a novel oral formulation of VK2735 showed dose-dependent reductions in mean body weight up to approximately 5.3%.
• A Phase 2 clinical trial of the oral tablet formulation of VK2735 was initiated in January 2025, with initial results expected in the second half of 2025.
• The VOYAGE study, a Phase 2b clinical trial of VK2809 in patients with NASH/MASH, achieved its primary endpoint with statistically significant reductions in liver fat content.
• 52-week histologic data from the VOYAGE study showed up to 75% of patients treated with VK2809 achieving NASH/MASH resolution with no worsening of fibrosis.
• A Phase 1b clinical trial of VK0214 in patients with X-ALD showed the drug to be safe and well-tolerated, with significant reductions in plasma levels of VLCFAs.
• The company intends to pursue partnering or licensing opportunities for VK0214 prior to conducting additional clinical studies.
• As of December 31, 2024, Viking had cash, cash equivalents, and investments totaling $902.6 million.
• The company believes its cash resources will be sufficient to fund operations through at least the first quarter of 2026.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to the clinical progress of key drug candidates and a strong financial position. However, the inherent risks of drug development and the competitive landscape temper the overall sentiment.

Positives

• Significant reductions in body weight were observed in the Phase 2 VENTURE study of subcutaneous VK2735.
• Oral VK2735 demonstrated positive signs of clinical activity in a Phase 1 study.
• VK2809 showed statistically significant reductions in liver fat content in the Phase 2b VOYAGE study.
• VK0214 was shown to be safe and well-tolerated in a Phase 1b clinical trial, with significant reductions in plasma VLCFA levels.
• The company has a strong cash position to fund ongoing and planned clinical trials.

Negatives

• The company has incurred losses and negative cash flows from operations since its inception.
• The company is dependent on technologies licensed from Ligand Pharmaceuticals Incorporated.
• The company has not yet demonstrated an ability to obtain marketing approval for any of its drug candidates.
• The company may not be successful in obtaining or maintaining necessary rights to its drug candidates through acquisitions and in-licenses.

Risks

• Delays in the commencement or completion of clinical trials could result in increased costs and delay the ability to establish strategic collaborations.
• The company intends to rely on third parties to conduct preclinical studies and clinical trials, which poses risks if these parties do not successfully carry out their duties.
• Competitors may have drug candidates that are approved faster, are marketed more effectively, are better tolerated, have a more favorable safety profile or are demonstrated to be more effective.
• The company may not be successful in obtaining or maintaining necessary rights to its drug candidates through acquisitions and in-licenses.
• If the company fails to comply with its obligations in the agreements under which it in-licenses intellectual property and other rights from third parties, it could lose intellectual property rights that are important to its business.

Future Outlook

Viking Therapeutics expects to initiate Phase 3 clinical studies of the subcutaneous formulation of VK2735 in the first half of 2025 and complete the Phase 2 clinical trial of the oral tablet formulation of VK2735 in the second half of 2025.

Management Comments

• The document does not contain direct quotes from management, but it does reflect management's expectations and plans for future clinical trials and development programs.

Industry Context

Viking is operating in a competitive biopharmaceutical industry with rapidly advancing technologies and intense competition. The success of its drug candidates will depend on factors such as efficacy, safety, tolerability, and cost compared to existing and new therapies.

Comparison to Industry Standards

• VK2735, if approved, will compete against therapies already approved for obesity, including Semaglutide (Wegovy) and liraglutide (Saxenda) from Novo Nordisk A/S, and tirzepatide (Zepbound) from Eli Lilly and Company.
• Resmetirom (Rezdiffra) from Madrigal Pharmaceuticals, Inc., is the only therapy currently approved in the U.S. for the treatment of NASH/MASH, against which VK2809 would compete.
• Elivaldogene autotemcel from bluebird bio, Inc., has received accelerated approval by the FDA for CALD, which may be competitive with VK0214, if approved.
• VK5211, if approved, will face competition from experimental therapies in development for conditions characterized by muscle wasting by companies including Biophytis SA, and Helsinn Group.

Legal Proceedings

• The company is involved in legal proceedings against Ascletis Bioscience Co., Ltd., Gannex Pharma Co., Ltd., Ascletis Pharmaceuticals Co., Ltd., Ascletis Pharma Inc., and Jinzi Jason Wu, alleging violation of trade secrets and related claims.
• The ITCs Chief Administrative Law Judge issued a Notice of his determination in favor of Viking.

Related Party Transactions

• The company has a Master License Agreement with Ligand Pharmaceuticals Incorporated, which grants the company exclusive worldwide rights to certain clinical and preclinical programs.

Stakeholder Impact

• Shareholders: The clinical progress and financial stability are positive for shareholders, but risks remain.
• Employees: Continued employment and potential for growth within the company.
• Patients: Potential for new and improved therapies for metabolic and endocrine disorders.
• Partners: Opportunities for collaboration and licensing agreements.

Next Steps

• Initiate Phase 3 clinical studies for subcutaneous VK2735 in the first half of 2025.
• Complete Phase 2 clinical trial of oral tablet formulation of VK2735 and report initial results in the second half of 2025.
• Pursue partnering or licensing opportunities for VK0214 prior to conducting additional clinical studies.
• Continue to pursue partnering or licensing opportunities for VK5211 prior to conducting additional clinical studies.

Key Dates